MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.530
-0.310
-6.41%
After Hours: 4.750 +0.22 +4.86% 17:55 03/27 EDT
OPEN
4.710
PREV CLOSE
4.840
HIGH
4.836
LOW
4.530
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
11.03
52 WEEK LOW
3.260
MARKET CAP
328.71M
P/E (TTM)
-12.6466
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VKTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VKTX stock price target is 22.10 with a high estimate of 41.00 and a low estimate of 12.00.

EPS

VKTX News

More
  • Top Drug Stocks Under $5
  • MotleyFool.com · 3d ago
  • Biotech stocks have held up better than the broader market and these five are potential winners
  • MarketWatch · 5d ago
  • Top Pharma Stocks Under $5
  • MotleyFool.com · 5d ago
  • Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
  • Simply Wall St. · 6d ago

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
More

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.